ReviewPostepy dermatologii i alergologii2025
Classical and biological treatments in mycosis fungoides/Sézary syndrome. New horizons in oncodermatology.
Review in Postepy dermatologii i alergologii, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the strategic management of mycosis fungoides (MF)/Sézary syndrome (SS), an interdisciplinary framework is essential. The regimen typically encompasses dermatological-specific interventions, biologic response modulators, and, in advanced scenarios, systemic chemotherapeutic entities. This might integrate biologic response agents like bexarotene, histone deacetylase inhibitors such as romidepsin, and specialized monoclonal antibodies or conjugates, notably mogamulizumab and brentuximab vedotin. Decisions in therapeutic avenues are intricately individualized, considering determinants like patient age, functional health metrics, disease scope, evolutionary trajectory and previous therapeutic exposures. The high-frequency ultrasound seems to be a useful tool for monitoring infiltration of the skin. Moreover, ongoing studies are investigating novel therapeutic agents that may demonstrate efficacy in MF/SS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.